We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-9.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.21B
AUM Growth
-$432M
Cap. Flow
-$92.5M
Cap. Flow %
-4.18%
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$14.4M
2
CNC icon
Centene
CNC
+$8.41M
3
SNY icon
Sanofi
SNY
+$6.73M
4
LLY icon
Eli Lilly
LLY
+$6.66M
5
IQV icon
IQVIA
IQV
+$6.64M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$15.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
3
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
4
MDCO
Medicines Co
MDCO
+$10.3M
5
ELV icon
Elevance Health
ELV
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 95.66%
2 Real Estate 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLLS
176
Cellectis
CLLS
$279M
$1.01M 0.05%
110,147
– –
EIDX
177
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$980K 0.04%
20,000
– –
GRFS
178
Grifois
GRFS
$5.4B
$954K 0.04%
+47,373
New +$1.06M
SGMO
179
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$954K 0.04%
149,835
– –
MYOK
180
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$905K 0.04%
19,300
– –
AERI
181
DELISTED
Aerie Pharmaceuticals
AERI
$900K 0.04%
66,688
– –
MDGL icon
182
Madrigal Pharmaceuticals
MDGL
$11.9B
$891K 0.04%
13,340
– –
XLV icon
183
State Street Health Care Select Sector SPDR ETF
XLV
$42.3B
$891K 0.04%
10,055
-43,718
-81% -$4.25M
PTLA
184
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$779K 0.04%
109,246
-52,653
-33% -$657K
AXNX
185
DELISTED
Axonics, Inc. Common Stock
AXNX
$714K 0.03%
28,100
– –
RGNX icon
186
Regenxbio
RGNX
$672M
$703K 0.03%
21,700
-13,800
-39% -$575K
RUBY
187
DELISTED
Rubius Therapeutics, Inc
RUBY
$694K 0.03%
155,982
+87,609
+128% +$651K
NTLA icon
188
Intellia Therapeutics
NTLA
$1.53B
$673K 0.03%
55,050
– –
SNR
189
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$656K 0.03%
256,398
+98,351
+62% +$628K
PBYI icon
190
Puma Biotechnology
PBYI
$397M
$602K 0.03%
71,340
– –
IMGN
191
DELISTED
Immunogen Inc
IMGN
$574K 0.03%
168,190
– –
CHCT
192
Community Healthcare Trust
CHCT
$441M
$570K 0.03%
14,900
– –
MTEM
193
DELISTED
Molecular Templates, Inc.
MTEM
$562K 0.03%
2,821
– –
ZYME icon
194
Zymeworks
ZYME
$1.73B
$539K 0.02%
15,192
– –
PRGO icon
195
Perrigo
PRGO
$1.84B
$520K 0.02%
10,818
– –
NHI icon
196
National Health Investors
NHI
$3.64B
$497K 0.02%
+10,038
New +$762K
CDTX
197
DELISTED
Cidara Therapeutics
CDTX
$484K 0.02%
9,763
+1,824
+23% +$109K
YARW
198
Yarrow Bioscience, Inc. Common Stock
YARW
$101M
$478K 0.02%
+49
New +$769K
MOR
199
DELISTED
MorphoSys AG American Depositary Shares
MOR
$476K 0.02%
19,390
– –
CYH icon
200
Community Health Systems
CYH
$416M
$393K 0.02%
117,735
-86,200
-42% -$349K
6 7
8
9 10

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Tekla Capital Management held 227 positions worth $2.21B, down 16% from $2.64B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $92.5M in Q1 2020, closing 10 positions and reducing 76 holdings. Its most notable exit was Medicines Co, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Moderna worth $7.61M.

  • Tekla Capital Management's largest Q1 2020 buy was Moderna: 254,146 shares worth $7.61M.
  • Tekla Capital Management added most to Biogen in Q1 2020, an estimated $14.4M increase.
  • Tekla Capital Management's biggest Q1 2020 reduction was Merck, cutting an estimated $15.5M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $10.3M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.21B portfolio in Q1 2020.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q1 2020.
  • Tekla Capital Management's portfolio value fell 16% quarter-over-quarter to $2.21B.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.